Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

Area of Science:

• Biomarker discovery and validation
• Precision medicine and personalized therapeutics
• Diagnostic technology development

Background:

• Companion diagnostics (CDx) enable personalized treatment plans based on individual biomarker profiles, enhancing therapeutic efficacy and potentially reducing healthcare costs.
• Established models in oncology utilize targeted therapies (e.g., EGFR, HER2, PD-1/PD-L1) driven by biomarkers.
• Rapid technological advancements and complex resistance mechanisms pose challenges for CDx development and application.

Purpose of the Study:

• To comprehensively review the evolving regulatory landscape of companion diagnostics.
• To examine current clinical applications of CDx across solid tumors and hematologic malignancies.
• To explore diverse methodological platforms and persistent barriers in CDx development.

Main Methods:

• Literature review synthesizing current knowledge on CDx.
• Analysis of regulatory frameworks and clinical applications.
• Evaluation of diagnostic platforms including NGS, IHC, liquid biopsies, and point-of-care testing.

Main Results:

• Companion diagnostics are integral to precision medicine, with established roles in oncology.
• Diverse platforms exist, from traditional methods like IHC to emerging liquid biopsies and POC testing.
• Key challenges include tumor heterogeneity, standardization, biopsy trade-offs, and economic factors.

Conclusions:

• Companion diagnostics face evolving challenges but are vital for personalized medicine.
• Synergistic development of drugs and diagnostics is crucial.
• Future integration into AI-enhanced, multiomics-driven healthcare ecosystems is projected.